Human neutralizing antibodies elicited by SARS-CoV-2 infection

Cited by (1,008)

Items 601–700 of 1,008

1. Performance of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies in South Africa
   Maemu Petronella Gededzha, Nakampe Mampeule, Sarika Jugwanth, Nontobeko Zwane, Anura David, Wendy A. Burgers, Jonathan Michael Blackburn, Jurette S. Grove, Jaya A. George, Ian Sanne et al. · 2021 · PLoS ONE
2. Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting
   Blake Marie Hauser, Maya Sangesland, Kerri St. Denis, Evan Christopher Lam, James Brett Case, Ian W. Windsor, Jared E. Feldman, Timothy M. Caradonna, Ty Kannegieter, Michael Diamond et al. · 2022 · Cell Reports
3. RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants
   Qingtai Liang, Yifeng Wang, Shuyuan Zhang, Jing Sun, Wenbo Sun, Jizhou Li, Yaping Liu, Mingxi Li, Lin Cheng, Yuhang Jiang et al. · 2022 · iScience
4. Regenerable and high-throughput surface plasmon resonance assay for rapid screening of anti-SARS-CoV-2 antibody in serum samples
   Meng Jiang, Tianbao Dong, Chaowei Han, Luyao Liu, Tiantian Zhang, Qing Kang, Pengcheng Wang, Feimeng Zhou · 2022 · Analytica Chimica Acta
5. Development of novel spectroscopic and machine learning methods for the measurement of periodic changes in COVID-19 antibody level
   Zozan Güleken, Yeşim Tok, Paweł Jakubczyk, Wiesław Paja, Krzysztof Pancerz, Yaroslav Shpotyuk, J. Cebulski, Joanna Depciuch · 2022 · Measurement
6. Immune responses to SARS‐CoV ‐2 vaccination in multiple sclerosis: a systematic review/meta‐analysis
   Grace Yoonheekim Gombolay, Monideep Dutt, William R. Tyor · 2022 · Annals of Clinical and Translational Neurology
7. Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2
   Meng Yuan, Yiquan Wang, Huibin Lv, Timothy J.C. Tan, Ian A. Wilson, Nicholas C. Wu · 2022 · Cell Reports
8. Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including the emerging EG.5 lineages
   Ling Li, Xixian Chen, Zuowei Wang, Yunjian Li, Chen Wang, Liwei Jiang, Teng Zuo · 2023 · PLoS Pathogens
9. A database of anti-coronavirus peptides
   Qianyue Zhang, Xue Chen, Bowen Li, Chunying Lu, Shanshan Yang, Jinjin Long, Heng Chen, Jian Hua Huang, Bifang He · 2022 · Scientific Data
10. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity
    J. Jensen, R. Sankhala, V. Dussupt, Hong-Jun Bai, A. Hajduczki, Kerri G. Lal, William C. Chang, E. Martinez, Caroline E. Peterson, Emily Golub et al. · 2023 · Journal of Virology
11. Inhalable materials and biologics for lung defence and drug delivery
    Savannah Weihang Zhang, David A. Edwards, R. Langer, K. Cheng · 2025 · Nature Reviews Materials
12. In silico Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19
    Andrés López‐Cortés, Patricia Guevara‐Ramírez, Nikolaos C. Kyriakidis, Carlos Barba‐Ostria, Ángela León Cáceres, Santiago Xavier Guerrero, Esteban Ortiz‐Prado, Cristian Robert Munteanu, Eduardo Tejera, Doménica Cevallos-Robalino et al. · 2021 · Frontiers in Pharmacology
13. Biological characteristics and biomarkers of novel SARS-CoV-2 facilitated rapid development and implementation of diagnostic tools and surveillance measures
    Gajanan Sampatrao Ghodake, Surendra Krushna Shinde, Avinash Ashok Kadam, Rijuta Ganesh Saratale, Ganesh Dattatraya Saratale, Asad Syed, Abdallah Mohamed Elgorban, Najat Marraiki, Dae-Young Kim · 2021 · Biosensors and Bioelectronics
14. Ultrasensitive, high-throughput, and rapid simultaneous detection of SARS-CoV-2 antigens and IgG/IgM antibodies within 10 min through an immunoassay biochip
    Chunhua Wang, Chao Wang, Jiaoyan Qiu, Jianwei Gao, Hong Liu, Yu Zhang, Lin Ge Han · 2021 · Microchimica Acta
15. Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen
    Min Jiang, Gaiping Zhang, Hongliang Liu, Peiyang Ding, Yunchao Liu, Yuanyuan Tian, Yanwei Wang, Aiping Wang · 2021 · Frontiers in Immunology
16. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans
    David Forgacs, Hyesun Jang, Rodrigo B. Abreu, Hannah B. Hanley, Jasper L. Gattiker, Alexandria M. Jefferson, Ted M. Ross · 2021 · Frontiers in Immunology
17. Stapled Peptides Targeting SARS-CoV-2 Spike Protein HR1 Inhibit the Fusion of Virus to Its Cell Receptor
    Mengjun Zheng, Wei Cong, Haoran Peng, Jie Qing, Huaxing Shen, Yaxin Tang, Chenchen Geng, Si Chen, Yan Zou, Weidong Zhang et al. · 2021 · Journal of Medicinal Chemistry
18. Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: A systematic review
    Hamid Aria, Fatemeh Mahmoodi, Hooria Seyedhosseini Ghaheh, Faranak Mavandadnejad, Hamed Zare, Mohammad Heiat, Hamid Bakherad · 2022 · Analytical Biochemistry
19. CD8+ T-Cell Epitope Variations Suggest a Potential Antigen HLA-A2 Binding Deficiency for Spike Protein of SARS-CoV-2
    Congling Qiu, Chanchan Xiao, Zhigang Wang, Guodong Zhu, Lipeng Mao, Xiongfei Chen, Lijuan Gao, Jieping Deng, Jun Su, Huanxing Su et al. · 2022 · Frontiers in Immunology
20. A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines
    Naru Zhang, Kangchen Li, Zezhong Liu, Kutty Selva Nandakumar, Shibo Jiang · 2022 · Viruses
21. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion
    Chia‐Jung Li, Tai‐Ling Chao, Ting-Yu Chang, Chia-Chun Hsiao, De-Chao Lu, Yi-Wei Chiang, Guan-Chun Lai, Ya‐Min Tsai, Jun‐Tung Fang, Si‐Man Ieong et al. · 2022 · Microbiology Spectrum
22. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
    Ying-Dan Wang, Xiang Zhang, Yunping Ma, Yanqun Wang, Wuqiang Zhan, Qinwen Zheng, Meng Zhang, Ping Ji, Mei Liu, Qianying Liu et al. · 2022 · Cell Discovery
23. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2
    Qian Wang, Zhiteng Li, Yicheng Guo, Ian A. Mellis, Sho Iketani, Michael Liu, Jian Yu, Riccardo Valdez, Adam S. Lauring, Zizhang Sheng et al. · 2023 · iScience
24. Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants
    Yanqun Wang, An Yan, Deyong Song, Maoqin Duan, Chuangchuang Dong, Jiantao Chen, Zihe Jiang, Yuanzhu Gao, Muding Rao, Jianxia Feng et al. · 2024 · Nature Communications
25. Structural Immunology of SARS ‐ CoV ‐2
    Meng Yuan, Ian A. Wilson · 2024 · Immunological Reviews
26. Phylogenetic analysis of SARS‐CoV‐2 in the first few months since its emergence
    Matías Javier Pereson, Laura Noelia Mojsiejczuk, Alfredo P. Martínez, Diego Martin Flichman, Gabriel H. Garcia, Federico Alejandro Di Lello · 2020 · Journal of Medical Virology
27. Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset
    Varun Sasisekharan, Niharika Pentakota, Akila Jayaraman, Kannan Tharakaraman, G. Wogan, Uma Narayanasami · 2021 · Proceedings of the National Academy of Sciences of the United States of America
28. Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalised COVID-19 patients
    Cláudia Serre-Miranda, Cláudia Nóbrega, Susana Roque, João Canto-Gomes, Carolina Sousa Silva, Neide Vieira, Palmira Barreira‐Silva, Pedro Alves-Peixoto, Jorge Cotter, Ana Batalha Reis et al. · 2021 · International Journal of Infectious Diseases
29. What do we know about the antibody responses to SARS-CoV-2?
    Francisco Alejandro Lagunas‐Rangel, Venice Chávez‐Valencia · 2021 · Immunobiology
30. Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein
    Shweta Alai, Nidhi Gujar, Manali Joshi, Manish Gautam, Sunil Gairola · 2021 · Heliyon
31. Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19
    Yanghong Ni, Aqu Alu, Lei Hong, Yang Wang, Min Wu, Xiawei Wei · 2021 · Molecular Biomedicine
32. Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis
    Eun-Jin Lee, Ji Eun Oh · 2021 · Molecules and Cells
33. Identification of COVID-19 B-cell epitopes with phage-displayed peptide library
    Jing-You Guo, I-Ju Liu, Hsiu-Ting Lin, Mei-jung Sebrina Wang, Yu‐Ling Chang, Shin-Chang Lin, Mei‐Ying Liao, Wei-Chia Hsu, Yi‐Ling Lin, James C. Liao et al. · 2021 · Journal of Biomedical Science
34. Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation
    Hsu-Yu Chen, Chun Huang, Lu Tian, Xiaoli Huang, Chennan Zhang, George N. Llewellyn, Geoffrey L. Rogers, Kevin Andresen, Maurice R.G. O’Gorman, Ya‐Wen Chen et al. · 2021 · Journal of Virology
35. Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern
    Teresa R. Wagner, Daniel Schnepf, Julius Beer, Karin Klingel, Natalia Ruetalo, Philipp D. Kaiser, Daniel Junker, Martina Sauter, Bjoern Traenkle, Desiree Isabella Frecot et al. · 2021 · EMBO Reports
36. SARS-CoV-2 Infection and Antiviral Strategies: Advances and Limitations
    Vinícius Cardoso Soares, Isabela Batista Gonçalves Moreira, Suelen da Silva Gomes Dias · 2025 · Viruses
37. SARS‐CoV‐2 immunogenicity at the crossroads
    Fariba Karamloo, Renate König · 2020 · Allergy
38. Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics
    Negin Ebrahimi, Saeed Aslani, Farhad Babaie, Maryam Hemmatzadeh, Ramin Hosseinzadeh, Zeinab Joneidi, Zahra Mehdizadeh Tourzani, Nafiseh Pakravan, Hamed Mohammadi · 2020 · International Immunopharmacology
39. Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19
    Hamed Fouladseresht, Mehrnoosh Doroudchi, Najmeh Rokhtabnak, Hossein Abdolrahimzadehfard, Amir Roudgari, Golnar Sabetian, Shahram Paydar · 2020 · Cytokine & Growth Factor Reviews
40. High neutralizing potency of swine glyco‐humanized polyclonal antibodies against SARS‐CoV‐2
    Bernard Vanhove, Odile Duvaux-Miret, Juliette Rousse, Pierre‐Joseph Royer, Gwénaëlle Evanno, Carine Ciron, Elsa Lhériteau, Laurent Vacher, Nadine Gervois, Romain Oger et al. · 2021 · European Journal of Immunology
41. The role and uses of antibodies in COVID-19 infections: a living review
    D. O. Scourfield, Sophie G. Reed, Max N. Quastel, Jennifer Alderson, Valentina M. T. Bart, Alicia Teijeira Crespo, Ruth Jones, Ellie Pring, F. Richter, Stephanie E. A. Burnell · 2021 · Oxford Open Immunology
42. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection
    Mingxi Li, Jingao Guo, Shuai-Yao Lu, Run-Hong Zhou, Hong-Yan Shi, Xuan-Ling Shi, Lin Cheng, Qing Liang, Hong-Qi Liu, Pui Wang et al. · 2021 · Frontiers in Immunology
43. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients
    Natalia Ruétalo, Ramona Businger, Karina Althaus, Simon Fink, Felix Ruoff, Michaela Pogoda, Angelika Iftner, Tina Ganzenmueller, Klaus Hamprecht, Bertram Flehmig et al. · 2021 · mSphere
44. Blockade of SARS-CoV-2 spike protein-mediated cell–cell fusion using COVID-19 convalescent plasma
    Ling Wang, Juan Zhao, Lam Nhat Nguyen, James L. Adkins, Madison Schank, Sushant Khanal, Lam Nhat Nguyen, Xindi Dang, Dechao Cao, Bal Krishna Chand Thakuri et al. · 2021 · Scientific Reports
45. Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India
    Kaustuv Nayak, Kamalvishnu P. Gottimukkala, Sanjeev Kumar, Elluri Seetharami Reddy, Venkata Viswanadh Edara, Robert C. Kauffman, Katharine A. Floyd, Grace E. Mantus, Deepali Savargaonkar, Pawan Kumar Goel et al. · 2021 · Virology
46. Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral Evolution
    Ida Monrad, Signe Risgaard Sahlertz, Stine Sofie Frank Nielsen, Louise Ørnskov Pedersen, Mikkel Steen Petersen, Carl Mathias Kobel, Irene Harder Tarpgaard, Merete Storgaard, Klaus Leth Mortensen, Mariane Høgsbjerg Schleimann et al. · 2021 · Open Forum Infectious Diseases
47. Track-etched membrane microplate and smartphone immunosensing for SARS-CoV-2 neutralizing antibody
    Cong Wang, Ze Wu, Bochao Liu, Panli Zhang, Jinhui Lu, Jinfeng Li, Peng Zou, Tingting Li, Yongshui Fu, Ruiai Chen et al. · 2021 · Biosensors and Bioelectronics
48. Potent neutralization of SARS‐CoV ‐2 including variants of concern by vaccines presenting the receptor‐binding domain multivalently from nanoscaffolds
    Peter Halfmann, Ana Castro, Kathryn Loeffler, Steven J. Frey, Shiho Chiba, Yoshihiro Kawaoka, Ravi S. Kane · 2021 · Bioengineering & Translational Medicine
49. Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
    Jingjing Zhang, Han Zhang, Li-Tao Sun · 2022 · mAbs
50. Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients
    M. Veronica Dioverti, David C. Gaston, C. Paul Morris, Carol Ann Huff, Tania Jain, Richard Jones, Viki Anders, Howard M. Lederman, Jacqueline Saunders, Heba H. Mostafa et al. · 2022 · Open Forum Infectious Diseases
51. Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trials
    Anton M. Sholukh, A. Fiore-Gartland, E. S. Ford, Y. Hou, Long-Ping V. Tse, F. Lempp, Hannah Kaiser, Russell Saint Germain, Emily L. Bossard, Jin-Kee Jia et al. · 2020 · medRxiv
52. Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron
    Da-Yuan Chen, D. Kenney, C. Chin, A. H. Tavares, Nazimuddin Khan, Hasahn L. Conway, Guanqun Liu, M. Choudhary, H. Gertje, A. O'Connell et al. · 2022 · bioRxiv
53. A novel recombinant S-based subunit vaccine induces protective immunity against porcine deltacoronavirus challenge in piglets
    Jizong Li, Shuqing Zhao, Baotai Zhang, Jin Huang, Qi Peng, Li Xiao, Xuesong Yuan, Rongli Guo, Jinzhu Zhou, Baochao Fan et al. · 2023 · Journal of Virology
54. Comparison of Immune Response between SARS, MERS, and COVID‐19 Infection, Perspective on Vaccine Design and Development
    Hossein Ansariniya, Seyed Mohammad Seifati, Erfan Zaker, Fateme Zare · 2021 · BioMed Research International
55. The role of pseudotype neutralization assays in understanding SARS CoV-2
    D. Cantoni, M. Mayora-Neto, N. Temperton · 2021 · Oxford Open Immunology
56. Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders
    Charlene Yat Che Chau, Loraine L. W. Chow, Siddharth Sridhar, Kendrick Co Shih · 2021 · Ophthalmology and Therapy
57. Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks
    Miao Cao, Xiaojie Su, Shibo Jiang · 2021 · Stem Cell Reports
58. SARS-CoV-2 cell entry and targeted antiviral development
    Zi-Nuo Chen, R. Du, Jazmin M. Galván Achi, Li-Jun Rong, Q. Cui · 2021 · Acta Pharmaceutica Sinica B
59. SARS-CoV-2: Origin, Evolution, and Targeting Inhibition
    Shuo Ning, Beiming Yu, Yanfeng Wang, Feng Wang · 2021 · Frontiers in Cellular and Infection Microbiology
60. Structural Comparison and Drug Screening of Spike Proteins of Ten SARS-CoV-2 Variants
    Qiangzhen Yang, Xuemin Jian, Ali Alamdar Shah Syed, Aamir Fahira, Chenxiang Zheng, Zijia Zhu, Ke Wang, Jinmai Zhang, Yanqin Wen, Zhiqiang Li et al. · 2022 · Research
61. Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease
    Bennett J. Davenport, Alexis Catala, S. Weston, Robert M. Johnson, J. Ardanuy, H. Hammond, C. Dillen, M. Frieman, C. Catalano, T. Morrison · 2021 · npj Vaccines
62. SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2
    Ruoke Wang, Qi Zhang, Rui Zhang, Zhen Qin Aw, Peng Chen, Yi Hao Wong, Junxian Hong, Bin Ju, Xuanling Shi, Qiang Ding et al. · 2022 · Frontiers in Immunology
63. Broadening a SARS-CoV-1–neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution
    Fang-Zhu Zhao, M. Yuan, Celina Keating, N. Shaabani, Oliver Limbo, Collin Joyce, J. Woehl, Shawn Barman, Alison Burns, Quoc Tran et al. · 2023 · Science Signaling
64. Expanding the Potential of Circular RNA (CircRNA) Vaccines: A Promising Therapeutic Approach
    Tian Bu, Wenlong Yang, Jian Zhao, Yanmei Gao, Faxiang Li, Rong Yang · 2025 · International Journal of Molecular Sciences
65. Targeting the SARS-CoV2 nucleocapsid protein for potential therapeutics using immuno-informatics and structure-based drug discovery techniques
    Alexander Kwarteng, Ebenezer Asiedu, Samuel Asamoah Sakyi, Samuel Opoku Asiedu · 2020 · Biomedicine & Pharmacotherapy
66. Man-Specific, GalNAc/T/Tn-Specific and Neu5Ac-Specific Seaweed Lectins as Glycan Probes for the SARS-CoV-2 (COVID-19) Coronavirus
    Annick Barre, Els J. M. Van Damme, Mathias Simplicien, Hervé Benoist, Pierre Rougé · 2020 · Marine Drugs
67. Overview of Nonhuman Primate Models of SARS-CoV-2.
    A. Trichel · 2021 · Comparative medicine
68. Secondary Structure and Conformational Stability of the Antigen Residues Making Contact with Antibodies
    Xinyue Qiao, Liang Qu, Yan Guo, Tyuji Hoshino · 2021 · The Journal of Physical Chemistry B
69. Landscapes and dynamic diversifications of B-cell receptor repertoires in COVID-19 patients
    Haitao Xiang, Yingze Zhao, Xinyang Li, Peipei Liu, Longlong Wang, Meiniang Wang, Lei Tian, Hai‐Xi Sun, Wei Zhang, Ziqian Xu et al. · 2021 · Human Immunology
70. Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
    Maryam Hojjat Jodaylami, Abdelhadi Djaïleb, Pierre Ricard, Étienne Lavallée, Stella Cellier-Goetghebeur, Megan-Faye Parker, Julien Coutu, Matthew Stuible, Christian Gervais, Yves Durocher et al. · 2021 · Scientific Reports
71. Evaluation of serological anti-SARS-CoV-2 chemiluminescent immunoassays correlated to live virus neutralization test, for the detection of anti-RBD antibodies as a relevant alternative in COVID-19 large-scale neutralizing activity monitoring
    Antonio Cristiano, Massimo Pieri, Serena Sarubbi, Martina Pelagalli, Graziella Calugi, Flaminia Tomassetti, Sergio Bernardini, Marzia Nuccetelli · 2021 · Clinical Immunology
72. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection
    K. M. Konrath, K. Liaw, Yuan-Han Wu, Xi-Zhou Zhu, Susanne N. Walker, Ziyang Xu, K. Schultheis, Neethu Chokkalingam, H. Chawla, Jianqiu Du et al. · 2022 · Cell Reports
73. SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets
    Pooja Shivshankar, Harry Karmouty‐Quintana, Tingting Mills, Marie–Françoise Doursout, Yanyu Wang, Agnieszka K. Czopik, Scott E. Evans, Holger K. Eltzschig, Xiaoyi Yuan · 2022 · Inflammation
74. Detection of neutralizing antibodies against multiple SARS-CoV-2 strains in dried blood spots using cell-free PCR
    Kenneth Danh, Donna Grace Karp, Malvika Singhal, Akshaya Tankasala, David Gebhart, Felipe de Jesus Cortez, Devangkumar Tandel, Peter V. Robinson, David Seftel, Mars Stone et al. · 2022 · Nature Communications
75. Computationally designed proteins mimic antibody immune evasion in viral evolution
    Noor Youssef, Sarah F. Gurev, Fadi Ghantous, Kelly P. Brock, Javier A. Jaimes, Nicole N. Thadani, Ann Dauphin, Amy C Sherman, Leonid Yurkovetskiy, Daria Soto et al. · 2025 · Immunity
76. Diagnosis of COVID-19: facts and challenges
    Haider Hashim Zalzala · 2020 · New Microbes and New Infections
77. Performance Characteristics of the Vidas SARS-CoV-2 IgM and IgG Serological Assays
    Nathalie Renard, Soizic Daniel, Nadège Cayet, Matthieu Pecquet, Frédérique Raymond, Sylvie Pons, Julien Lupo, Carole Tourneur, Catherine Pretis, Guillaume Gerez et al. · 2021 · Journal of Clinical Microbiology
78. Discovery and structural optimization of 3-O-β-chacotriosyl oleanane-type triterpenoids as potent entry inhibitors of SARS-CoV-2 virus infections
    Hui Li, Chen Cheng, Sumei Li, Yan Wu, Zhihao Liu, Mingjian Liu, Jianxin Chen, Qiuyu Zhong, Xuesha Zhang, Shuwen Liu et al. · 2021 · European Journal of Medicinal Chemistry
79. Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19
    Kun Xu, Yaling An, Qunlong Li, Wei-Jing Huang, Yuxuan Han, Tianyi Zheng, Fang Fang, Hui Liu, Chuan-Yu Liu, Ping Gao et al. · 2021 · Emerging Microbes and Infections
80. Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains
    Ki‐Back Chu, Hae-Ji Kang, Keon-Woong Yoon, Hae‐Ahm Lee, Eun‐Kyung Moon, Beom Ku Han, Fu‐Shi Quan · 2021 · Vaccines
81. Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines
    Ahmed Yaqinuddin, Areez Shafqat, Junaid Kashir, Khaled Manae AlKattan · 2021 · Vaccines
82. Neutralization of alpha, gamma, and D614G SARS‐CoV‐2 variants by CoronaVac vaccine‐induced antibodies
    Jorge Fernández, Nicole Bruneau, Rodrigo Fasce, Héctor San Martín, Monserrat Balanda, Patricia Bustos, Soledad Ulloa, Judith Mora, Eugenio Ramírez V · 2021 · Journal of Medical Virology
83. An overview of methods for the structural and functional mapping of epitopes recognized by anti-SARS-CoV-2 antibodies
    I. Francino-Urdaniz, T. Whitehead · 2021 · RSC Chemical Biology
84. A Structure-Based B-cell Epitope Prediction Model Through Combing Local and Global Features
    Shuai Lu, Yuguang Li, Qiang Ma, Xiaofei Nan, Shoutao Zhang · 2022 · Frontiers in Immunology
85. Antibody-mediated immunity to SARS-CoV-2 spike
    John M. Errico, Lucas J. Adams, Daved H. Fremont · 2022 · Advances in immunology
86. Amubarvimab/Romlusevimab: First Approval
    Sheridan M. Hoy · 2022 · Drugs
87. The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2
    Hualong Xiong, Hui Sun, Siling Wang, Lunzhi Yuan, Liqin Liu, Yuhe Zhu, Jinlei Zhang, Yang Huang, Ruoyao Qi, Yao Jiang et al. · 2022 · Proceedings of the National Academy of Sciences
88. Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses
    Mitch Brinkkemper, Tim S. Veth, Philip J. M. Brouwer, Hannah L. Turner, Meliawati Poniman, Judith A. Burger, Joey H. Bouhuijs, Wouter Olijhoek, Ilja Bontjer, Jonne L. Snitselaar et al. · 2022 · iScience
89. Variants of SARS-CoV-2: Influences on the Vaccines’ Effectiveness and Possible Strategies to Overcome Their Consequences
    Ali Ahmed Rabaan, Shamsah H. Al-Ahmed, Hawra Albayat, Sara M. Alwarthan, Mashael M. Alhajri, Mustafa A. Najim, Bashayer Mohammed Alshehail, Wasl Al-Adsani, Ali Alghadeer, Wesam A. Abduljabbar et al. · 2023 · Medicina
90. Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination
    Bin Ju, Qing Fan, Congcong Liu, Senlin Shen, Miao Wang, Huimin Guo, Bing Zhou, Xiangyang Ge, Zheng Zhang · 2023 · Cell Reports
91. The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2
    Jamie Guenthoer, Meghan E. Garrett, Michelle Lilly, Delphine Depierreux, Felicitas Ruiz, Margaret Chi, Caitlin I. Stoddard, Vrasha Chohan, Zak A. Yaffe, Kevin Sung et al. · 2024 · PLoS Pathogens
92. Coronaviruses pandemics: Can neutralizing antibodies help?
    Phuoc Bao Viet Tong, Li‐Yun Lin, Tuan Hiep Tran · 2020 · Life Sciences
93. Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2
    Y. Furuse, H. Oshitani · 2020 · Frontiers in Microbiology
94. Analysis of IgM, IgA, and IgG isotype antibodies Directed against SARS-CoV-2 spike glycoprotein and ORF8 in the course of COVID-19
    Denise Meinberger, Manuel Koch, Annika Roth, Gabriele Hermes, Jannik Stemler, Oliver A. Cornely, Thomas Streichert, Andreas R. Klatt · 2021 · Scientific Reports
95. SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing
    Jennifer A. Rathe, Emily A. Hemann, Julie Eggenberger, Zhaoqi Li, Megan L. Knoll, Caleb Stokes, Tien-Ying Hsiang, Jason Netland, Kennidy K. Takehara, Marion Pepper et al. · 2020 · The Journal of Infectious Diseases
96. ADAM17 is an essential attachment factor for classical swine fever virus
    Fei Yuan, Dandan Li, Changyao Li, Yanan Zhang, Hao Song, Suhua Li, Hongkui Deng, George F. Gao, Aihua Zheng · 2021 · PLoS Pathogens
97. A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection
    A. Tabll, Y. Shahein, M. Omran, M. Elnakib, Ameera Ragheb, Khaled Amer · 2021 · Human Antibodies
98. Binding affinity and mechanisms of SARS-CoV-2 variants
    Yanqiang Han, Zhilong Wang, Zhiyun Wei, Igor Schapiro, Jinjin Li · 2021 · Computational and Structural Biotechnology Journal
99. Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD
    John M. Errico, Haiyan Zhao, Rita E. Chen, Zhuoming Liu, James Brett Case, Meisheng Ma, Aaron J. Schmitz, Michael Rau, James A. J. Fitzpatrick, Pei‐Yong Shi et al. · 2021 · Cell Reports
100. Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects
     Antonio Cristiano, Marzia Nuccetelli, Massimo Pieri, Serena Sarubbi, Martina Pelagalli, Graziella Calugi, Flaminia Tomassetti, Sergio Bernardini · 2021 · International Immunopharmacology